Nektar Therapeutics (NKTR)

Currency in USD
30.200
-2.340(-7.19%)
Closed·
30.2000.000(0.00%)
·
Trading near 52-week Low
NKTR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.13032.350
52 wk Range
30.130109.000
Key Statistics
Prev. Close
30.2
Open
31.66
Day's Range
30.13-32.35
52 wk Range
30.13-109
Volume
1.02M
Average Volume (3m)
1.11M
1-Year Change
-44.3626%
Book Value / Share
24.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NKTR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
131.917
Upside
+336.81%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Nektar Therapeutics News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
4 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 131.917
(+336.81% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy149.00+393.38%153.00MaintainNov 16, 2026
Leerink
Buy130.00+330.46%-New CoverageOct 12, 2026
UBS
Hold53.00+75.50%-New CoverageOct 12, 2026
Raymond James
Hold---New CoverageOct 08, 2026
Citi
Buy151.00+400.00%-MaintainOct 05, 2026

Nektar Therapeutics Earnings Call Summary for Q3/2026

  • Nektar posted Q3 EPS of -$1.63, beating estimates of -$2.08, but revenue of $9.39M missed the $10.31M forecast by 8.92%.
  • Company ended quarter with $953M in cash and no debt; raised year-end cash guidance to over $840M, above prior range.
  • REZPEG advanced to Phase III trials for atopic dermatitis and alopecia areata; top-line AD data expected summer 2028, filing targeted 2029.
  • Full-year 2026 guidance: $38M non-cash royalty revenue, R&D spend $185M-$200M, G&A about $65M, non-cash interest expense $28M.
  • Shares fell 7.7% to $35.50 post-earnings despite EPS beat, as investors focused on revenue miss and extended commercialization timeline.
Last Updated: 2026-11-12, 06:30 p/m
Read Full Transcript

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-1.63 / -2.08
Revenue / Forecast
9.39M / 10.31M
EPS Revisions
Last 90 days

NKTR Income Statement

Compare NKTR to Peers and Sector

Metrics to compare
NKTR
Peers
Sector
Relationship
P/E Ratio
−5.8x−1.2x−0.2x
PEG Ratio
−0.29−0.030.00
Price/Book
1.2x1.6x2.6x
Price / LTM Sales
19.8x8.4x2.6x
Upside (Analyst Target)
336.8%262.0%77.0%
Fair Value Upside
Unlock21.2%13.7%Unlock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.41M36.26%374.69M
Other Institutional Investors
29.77M63.74%899.12M
Public Companies & Retail Investors
0.000.00%0.00
Total
42.18M100.00%1.27B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC14.97%5,121,430154,667
Two Seas Capital LP9.78%3,345,978101,049

People Also Watch

150.02
FTAI
-10.80%
129.36
AXSM
-4.66%
97.17
KOD
-0.75%
95.81
ORKA
-1.80%
4.210
PGEN
+1.20%

FAQ

What Is the Nektar (NKTR) Stock Price Today?

The Nektar stock price today is 30.200 USD.

What Stock Exchange Does Nektar Trade On?

Nektar is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Nektar?

The stock symbol for Nektar is "NKTR."

What Is the Nektar Market Cap?

As of today, Nektar market cap is 1.030B USD.

What Is Nektar's Earnings Per Share (TTM)?

The Nektar EPS (TTM) is -6.31.

When Is the Next Nektar Earnings Date?

Nektar will release its next earnings report on Mar 02, 2027.

From a Technical Analysis Perspective, Is NKTR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Nektar Stock Split?

Nektar has split 2 times.

How Many Employees Does Nektar Have?

Nektar has 63 employees.

What is the current trading status of Nektar (NKTR)?

As of Nov 22, 2026, Nektar (NKTR) is trading at a price of 30.200 USD, with a previous close of 30.200 USD. The stock has fluctuated within a day range of 30.130 USD to 32.350 USD, while its 52-week range spans from 30.130 USD to 109.000 USD.

What Is Nektar (NKTR) Price Target According to Analysts?

The average 12-month price target for Nektar is 131.917 USD, with a high estimate of 192 USD and a low estimate of 40 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +336.81% Upside potential.

What Is the NKTR Premarket Price?

NKTR's last pre-market stock price is 31.800 USD. The pre-market share volume is 15,110.000, and the stock has decreased by -0.740, or -2.270%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.